Ozempic
US$ 28.49
alternatives to glp-1 Drugs for Employers Natural GLP-1 Alternatives: Clinical Evidence
Description
Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight
While specific guidelines on continuing therapy after HbA1c normalization are lacking, current evidence supports ongoing use of these agents due to their insulin-independent mechanisms of action
Singh A, Sohal A, Batta A
Approval requires bioequivalence to the reference product
Lillys Oral GLP-1, Orforglipron, Delivers Weight Loss of Up to an Average of 27.3 Lbs in First of Two Pivotal Phase 3 Trials in Adults With Obesity
Patients urgently need this kind of health care organization.
